

**In the Claims:**

1. (Original) An isolated EBV CTL peptide epitope consisting of up to nine contiguous amino acid residues of an LMP1 protein, and comprising an amino acid sequence selected from the group consisting of:

- (i) QRH (SEQ ID NO:4);
- (ii) AGNDG (SEQ ID NO:5);
- (iii) QNW (SEQ ID NO:6), specifically excluding the sequence  
YLQQNWWTL (SEQ ID NO:1);
- (iv) VLYS (SEQ ID NO:7); and
- (v) DSNSNE (SEQ ID NO:8).

2. (Original) The isolated EBV CTL peptide epitope of Claim 1 consisting of an amino acid sequence selected from the group consisting of:

- (i) QRHSDEHHH (SEQ ID NO:9);
- (ii) GQRHSDEHH (SEQ ID NO:10);
- (iii) YYHGQRHSD (SEQ ID NO:11); and
- (iv) WMYYHGQRH (SEQ ID NO:12).

3. (Original) The isolated EBV CTL epitope of Claim 1 consisting of an amino acid sequence selected from the group consisting of:

- (i) AGNDGGPPQ (SEQ ID NO:16); and
- (ii) PSDSAGNDG (SEQ ID NO:17).

4. (Original) The isolated EBV CTL epitope of Claim 1 consisting of an amino acid sequence selected from the group consisting of:

- (i) IALYLQQNW (SEQ ID NO:21);
- (ii) ALYLQQNWW (SEQ ID NO:22);
- (iii) QNWWTLLVD (SEQ ID NO:23); and
- (iv) LYLQQNWWT (SEQ ID NO:24).

5. (Original) The EBV CTL peptide epitope of Claim 1 consisting of an amino acid sequence selected from the group consisting of:

- (i) LLVLYSFAL (SEQ ID NO:29);
- (ii) ALLVLYSFA (SEQ ID NO:30); and
- (iii) VLYSFALML (SEQ ID NO:31).

6. (Original) The EBV CTL peptide epitope of Claim 1 consisting essentially of an amino acid sequence selected from the group consisting of:

- (i) DSNSNEGRH (SEQ ID NO:37);and
- (ii) ESDSNSNEG (SEQ ID NO:2).

7. (Original) An isolated EBV CTL peptide epitope consisting of an amino acid sequence selected from the group consisting of: ESDSNSNEG (SEQ ID NO:2); QRHSDEHHH (SEQ ID NO:9); GQRHSDEHH (SEQ ID NO:10); YYHGQRHSD (SEQ ID NO:11); WMYYHGQRH (SEQ ID NO:12); YYHGQRHSDEHH (SEQ ID NO:13); IWMYYHGQRHSD (SEQ ID NO:14); LIWMYYHGQRHSDEHHH (SEQ ID NO:15); AGNDGGPPQ (SEQ ID NO:16); PSDSAGNDG (SEQ ID NO:17); SDSAGNDGGPPQ (SEQ ID NO:18); DSAGNDGGPPQL (SEQ ID NO:19); PHSPSDSAGNDGGPPQL (SEQ ID NO:20); IALYLQQNW (SEQ ID NO:21); ALYLQQNWW (SEQ ID NO:22); QNWWTLLVD (SEQ ID NO:23); LYLQQNWWT (SEQ ID NO:24); IALYLQQNWWTL(SEQ ID NO:25); YLQQNWWTLLVD (SEQ ID NO:26); LIIALYLQQNWWTLLVD (SEQ ID NO:27); ALLVLYSFAL(SEQ ID NO:28); LLVLYSFAL (SEQ ID NO:29); ALLVLYSFA (SEQ ID NO:30); VLYSFALML (SEQ ID NO:31); ALLVLYSFALML (SEQ ID NO:32); GALLVLYSFALM (SEQ ID NO:33); DWTGGALLVLYS (SEQ ID NO:34); GGALLVLYSFAL (SEQ ID NO:35); DWTGGALLVLYSFALML (SEQ ID NO:36); DSNSNEGRH (SEQ ID NO:37); SGHESDSNSNEG (SEQ ID NO:38); and TDDSGHESDSNSNEGRH (SEQ ID NO:39).

8. (Original) An isolated EBV CTL peptide epitope consisting of an amino acid sequence selected from the group consisting of: SEQ ID NO:2; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:21; SEQ ID NO:22; SEQ

ID NO:23; SEQ ID NO:24; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:31; and SEQ ID NO:37.

9. (Original) A variant of an isolated EBV CTL epitope that consists of an amino acid sequence differing by one, two or three amino acids from an amino acid sequence selected from the group consisting of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:28; SEQ ID NO:29; SEQ ID NO:30; SEQ ID NO:31; and SEQ ID NO:37.

10. (Original) The variant of Claim 9, comprising an amino acid sequence selected from the group consisting of:

- (i) an amino acid sequence differing from SEQ ID NO:1 by one amino acid;
- (ii) an amino acid sequence differing from SEQ ID NO:21 by one amino acid; and
- (iii) an amino acid sequence differing from SEQ ID NO:30 by one amino acid.

11. (Original) A variant of an isolated EBV peptide epitope having an amino acid sequence according to any one of SEQ ID NOS:40-44 and 47-50.

12. (Currently Amended) An isolated protein comprising at least one EBV CTL epitope and/or a EBV CTL epitope variant according to [[any one of Claims 1-11]] Claim 1.

13. (Currently Amended) The isolated protein of Claim [[13]] 12, comprising a plurality of EBV CTL epitopes and/or EBV CTL epitope variants.

14. (Original) The isolated protein of Claim 13 which is a polypeptide protein comprising an amino acid sequence selected from the group consisting of ALLVLYSFA (SEQ ID NO:30) and IALYQQNW (SEQ ID NO:21).

15. (Original) The isolated protein of Claim 14, wherein a plurality of the EBV CTL epitopes and/or EBV CTL epitope variants are contiguous.

16. (Original) The isolated polyepitope protein of Claim 15 comprising thirteen EBV CTL epitopes having the respective amino acid sequences YLLEMLWRL (SEQ ID NO: 3); YLQQNWWTL (SEQ ID NO: 1); ALLVLYSFA (SEQ ID NO:30); IAYLQQNW (SEQ ID NO:21); SSCSSCPLSKI (SEQ ID NO: 51); PYLFWLAAI (SEQ ID NO:52); TYGPVFMCL (SEQ ID NO:53); RRRWRRLTV (SEQ ID NO:54); LLSAWILTA (SEQ ID NO: 55); LTAGFLIFL (SEQ ID NO:56); VMSNTLLSAW (SEQ ID NO:57); IEDPPFNSL (SEQ ID NO:58); CLGGLLTMV (SEQ ID NO:59).

17. (Original) The isolated polyepitope protein of Claim 16 comprising the amino acid sequence set forth in SEQ ID NO:81.

18-26. (Cancelled)

27. (Currently Amended) A pharmaceutical composition comprising at least one isolated EBV CTL peptide epitope according to [[any one of Claims 1-18 and/or at least one isolated EBV peptide epitope variant according to any one of claims 9-11]] Claim 1, together with a pharmaceutically acceptable carrier, diluent or excipient.

28. (Original) The pharmaceutical composition of Claim 27 comprising an amino acid sequence selected from the group consisting of ALLVLYSFA (SEQ ID NO:30) and IALYQQNW (SEQ ID NO:21).

29. (Original) The pharmaceutical composition of Claim 27 comprising a polyepitope protein that comprises the amino acid sequence set forth in SEQ ID NO:81.

30-33. (Cancelled)

34. (Currently Amended) The pharmaceutical composition of [[any one of Claims 27-33]] Claim 27, which is an immunotherapeutic composition.

35. (Cancelled)

36. (Currently Amended) A method of therapeutically and/or prophylactically treating an EBV-associated disease, including the step of administering to an animal at least one isolated EBV CTL epitope according to [[any one of claims 1-12]] Claim 1.

37. (Original) The method of Claim 36 wherein the at least one epitope comprises an amino acid sequence selected from the group consisting of ALLVLYSFA (SEQ ID NO:30) and IALYQQNW (SEQ ID NO:21).

38. (Original) The method of Claim 35 wherein the at least one peptide epitope is a polypeptide protein that comprises the amino acid sequence set forth in SEQ ID NO:81.

39-41 (Cancelled).

42. (Currently Amended) The method of [[any one of Claims 36-41]] Claim 36, wherein the EBV associated disease is selected from B and T cell non-Hodgkin's lymphomas, Hodgkin's disease, and lymphoepithelioma-like carcinomas.

43. (Original) The method of Claim 42, wherein the EBV associated disease is nasopharyngeal carcinoma (NPC).

44. (Currently Amended) The method of [[any one of Claims 36-43]] Claim 36 wherein the animal is a mammal.

45. (Original) The method of Claim 44 wherein the mammal is a human.

46. (Original) The method of Claim 45 wherein one or more of the at least one EBV peptide epitopes is selected according to a HLA type of the human to be treated.

47-54 (Cancelled).